Informazioni sul prodotto
- (4R,6S)-6-[(1E)-2-[2-(Cyclopropyl-d5)-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one
- [4R-[4a,6ß(E)]]-6-[2-[2-(Cyclopropyl-d5)-4- (4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one
- NK 104-d5
- NK 104-d5 (lactone)
- Nisvastatin-d5
- P 872441-d5
- 4-(1-(4-Chlorobenzoyl)-6-imino-3-methyl-1,4,6,7-tetrahydropyrazolo[3,4-d][1,3]thiazin-4-yl)-2-methoxyphenol
- 4H-Pyrazolo[3,4-d][1,3]thiazin-6-amine, 1-(4-chlorobenzoyl)-4-(4-hydroxy-3-methoxyphenyl)-3-methyl-
- [6-amino-4-(4-hydroxy-3-methoxyphenyl)-3-methylpyrazolo[3,4-d][1,3]thiazin-1(4H)-yl](4-chlorophenyl)methanone
- (4R,6S,E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl-ethenylvinyl]-4-hydroxyl-3,4,5,6-H-2H-pyran-2-etone
- Vedi altri sinonimi
- Pitavastatin calcium intermediates to 5,(4R,6S,E)-6-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinoline-yl-vinyl]-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
Applications A labelled metabolite of Pitavastatin. Recent studies have shown that conversion between acid and lactone forms occurs in the body, drug-drug interaction should be considered on both acid and lactone forms. The inhibitory effects of statins on CYP metabolic activities and MDR1 transporting activity were investigated using human liver microsomes and MDR1-overexpressing LLC-GA5-COL150 cells.
References Wang, J., et al.: Drug Metab. Dispos., 30, 1352 (2002), Yamada, I., et al.: Xenobiotica, 33, 789 (2003), Fujino, H., et al.: Xenobiotica, 34, 961 (2004), Ando, H., et al.: Br. J. Clin. Pharmacol., 60, 494 (2005),
Proprietà chimiche
Richiesta tecnica su: TR-P531022 Pitavastatin-d5 Lactone
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.